Positive Family History As a Predictor for Disease Outcomes after Radical Prostatectomy for Nonmetastatic Prostate Cancer

Pawel Rajwa,Fahad Quhal,David D'Andrea,Stephan Korn,Patrik Petrov,Takafumi Yanagisawa,Tatsushi Kawada,Reza Sari Motlagh,Hadi Mostafaei,Ekaterina Laukhtina,Abdulmajeed Aydh,Frederik Koenig,Maximilian Pallauf,Benjamin Pradere,Peter Nyirady,Mohammad Abufaraj,Giancarlo Marra,Giorgio Gandaglia,Alberto Briganti,Pierre Karakiewicz,Ding-wei Ye,Martin Haydter,Piotr Chlosta,Eva Comperat,Dmitry Enikeev,Shahrokh F. Shariat
DOI: https://doi.org/10.1080/2090598x.2023.2196911
2023-01-01
Arab Journal of Urology
Abstract:BackgroundWhile family history (FHx) of prostate cancer (PCa) increases the risk of PCa, comparably less is known regarding the impact of FHx on pathologic and oncologic outcomes after radical prostatectomy (RP).MethodsWe retrospectively reviewed our multicenter database comprising 6,041 nonmetastatic PCa patients treated with RP. Patients with a FHx of PCa in one or more first-degree relatives were considered as FHx positive. We examined the association of FHx with pathologic outcomes and biochemical recurrence (BCR) using logistic and Cox regression models, respectively.ResultsIn total, 1,677 (28%) patients reported a FHx of PCa. Compared to patients without FHx, those with, were younger at RP (median age of 59 vs. 62 years, p < 0.01), and had significantlymore favorable biopsy and RP histopathologic findings. On multivariable logistic regression analysis, positive FHx was associated with extracapsular extension (odds ratio [OR] 0.77, 95% confidence interval [CI] 0.66-0.90, p < 0.01; model AUC 0.73) and upgrading (OR 0.70, 95% CI 0.62-0.80, p < 0.01; model AUC 0.68). Incorporating FHx significantly improved the AUC of the base model for upgrading (p < 0.01). Positive FHx was not associated with BCR in pre- and postoperative multivariable models (p = 0.1 and p = 0.7); c-indexes of Cox multivariable models were: 0.73 and 0.82, respectively.ConclusionsWe found that patients with clinically nonmetastatic PCa who have positive FHx of PCa undergo RP at a younger age and have more favorable pathologic outcomes. Nevertheless, FHx of PCa did not confer better BCR rates, suggesting that FHx leads to potentially early detection and treatment without impact on BCR.
What problem does this paper attempt to address?